Sepsis like a severe complication of autoimmune liver disease in gastroenterological patients

In article we present particular qualities of disease pattern and methods of treatment in patients with ulcer colitis associated with primary sclerosing cholangitis and autoimmune hepatitis. Course of disease was complicated by bacterial cholangitis, sepsis, multiple organ failure. There are described pathogenetic features of autoimmune livers and bowel illness. It was shown the role of bacterial translocation of microbes. There are described about differential diagnostic of primary and secondary cholangitis. Features of curing the patients are reminded in critical conditions are reviewed in article. There sketched role of glucocorticosteroids in critical care. Modern guidelines for the management the patients with overlap syndrome are highlighted. Patient D. was admitted to hospital in intensive care unit. There disease patterns of collapse, systemic inflammation response syndrome. The examination was established exacerbation of ulcer colitis complicated inflectional morbidity with sclerosing cholangitis and autoimmune hepatitis. This condition led to sepsis and multiple organ failure. Instead of intensive care there was a progressive deterioration until near death experience. Resuscitation procedure within 6 minutes were successful. Multiple areas of necrosis have developed on the limbs because of multiple organ failure and intensive vasopressors therapy. Glucocorticosteroids were prescribed in combination with antibacterial drugs were assigned because of ulcerative colitis’s exacerbation and cytolysis, regardless sepsis. On the thirtieth day of stay in hospital, the patient D. was transferred from the intensive care unit to the gastroenterology department, where the treatment was continued. Because of the cure signs of multiple organ failure, infectious complications, exacerbation of ulcerative colitis and primary sclerosing cholangitis were regressed. We supervise of patient.

1. Cosnes J., Gower-Rousseau C., Seksik P., Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140:1785-1794.

2. Ivashkin V.T., Shelgin Yu.A., Khalif A.L. et al. Clinical guide of Russian association of gastroenterology and coloproctology on diagnostics and treatment of ulcerative colitis. Koloproctologia (Coloproctology) Journal of Russian association of coloproctology. 2017; 1(59):7-31 [in Russian].

3. Brown S.R., Haboubi N., Hampton J. et al. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis. 2008; 10:8-29.

4. Saich R., Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008; 14(3):331-337.

5. Liu J.Z., Hov J.R., Folseraas T. et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat. Genet. 2013; 45:670-675.

6. Berg R.D. Translocaision of certain indigenous bacteria form the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infection and immunology. 1979; 23(2): 403-411.

7. Braun J. Multiparameter Analysis OfImmunogenetic Mechanism In Clinical Diagnosis And Management Of Inflammatory Bowel Disease. Advances in Experimental Medicine and Biology.2006; 579: 209-218.

8. Papadakis K.A. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann Rev Med. 2000; 51: 289-298.

9. Bergquist A. Primary Sderosing Cholangitis in EASL The Home of Hepatology. Amsterdam, the Neterlands. 2017;82-85.

10. Lasebnic L.B., Ribak V.S. Ilchenko L.Yu. Primary sclerosing cholangitis. ConsiliumMedicum, 2003; 6: 28-30 [ in Russian].

11. Chapman R., Fevery J., Kalloo A., et al. Diagnosis and manangement of Primary Sderosing Cholangitis. Hepatology 2010; 51(2):660-668.

12. Mishnev O.D., Tumanova U.N., Schegolev A.I., Pathology of the liver in sepsis. Internation Journal of applied and fundamental research. 2017; 8(2): 267-271 [in Russian].

13. Ivashkin V.T., Shirokova V.T., Maevskaia M.V. at. al. Clinical guidelines of the Russian gastroenterological association and the Russian society on study of the liver on diagnostics and treatment of cholestasis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015; 2: 41-57 [in Russian].

14. European Society of Gastrointestinal Endoscopy, European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. J Hepatol. 2017; 66(6): 1265-1281.

15. Keith D., Lindor M.D., Kris V. et al. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Gastroenterology. 2015; 110(5): 646-659.

16. Barosa R., Roque Ramos L., Patita M. et al. CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on chronic liver failure admitted to the ward.Rev EspEnferm Dig. 2017; 109(6):399-405.

17. Rhodes A., Evans L.E., Mitchell M. at al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2016. Intensive care med. 2017; 43(3): 304-377.

18. Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus fludrocortisones for adults with septic shock. N Engl J Med. 2018; 378:809-818.

19. ConsiliumMedicum. 2017; 8: 121-130. Raschelson K.L., Pazeco E.V, Marchenko N.V. Primary sclerosing cholangitis: review of recomdations for treatment and diagnosis. ConsiliumMedicum. 2017; 8: 121-130 [in Russian].

20. Kremleva O.V. Problems of non-compliance in somatic clinic.the way of overcome. [Electronic source]. Medical psychology in Russia. 2013;4(21): URL: http://mprj.ru (Date of the application15.11.18) [in Russian].